This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biogen's MS Pill Roars Out Of Launch Gate

CAMBRIDGE, Mass. ( TheStreet) -- Biogen Idec's (BIIB - Get Report) multiple sclerosis pill Tecfidera is off to a blazing commercial launch.

Check out the green, nearly vertical line, in the graph above. It represents one week of Tecfidera scripts, per IMS Health. As ISI Group analyst Mark Schoenebaum points out, Biogen booked as many Tecfidera scripts in one week as Novartis (NVS - Get Report) did with Gilenya after three months.

Biogen shares are up 4% to $210.73 in early trading.

Yes, we're only looking at a single week of Tecfidera scripts, so it's way too early to reach any definitive conclusions. Still, pretty cool if you're Biogen or one of its shareholders.

"Any way you look at it, BG-12 appears to be doing very well in its inaugural week," writes Schoenebaum in an email to clients Monday morning, referring to Tecfidera's scientific name. Schoenebaum also created and sent out the graph.

Biogen reports first-quarter financial results on Thursday morning, with current consensus at earnins of $1.61 per share on total revenue of $1.42 billion. Tecfidera was approved at the end of March, so sales won't factor much into first-quarter results. Still, investors will definitely want to hear from Biogen management about the early weeks of the launch.

For the year, Biogen is expected to earn $7.79 per share on total revenue of $6.43 billion. Included in the consensus revenue estimate is approximately $240 million in Tecfidera sales.

If that slope of that green line in the graph above remains vertical, investors are under-estimating Tecfidera sales -- and Biogen earnings.

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
BIIB $263.70 -3.70%
NVS $74.31 -2.40%
AAPL $94.26 -0.97%
GOOG $697.34 0.72%
FB $117.96 0.45%


Chart of I:DJI
DOW 17,650.20 -100.71 -0.57%
S&P 500 2,050.15 -13.22 -0.64%
NASDAQ 4,724.0390 -39.1850 -0.82%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs